In the last year, a nine-gene signature, including two negative impact factors (NR1I2 and LGALSL) and seven positive ones (C1ORF198, CST2, LAMP5, FOXS1, CES1P1, MMP7 and COL8A1), was proposed to predict the outcome of GC, and the model was able to predict patients’ outcome in terms of survival and recurrence, clustering GC cases into low-risk and high-risk groups [18]. This evidence concerns the gene NR1I2 and gastric cancer.